title: What is proper treatment for Wegener granulomatosis?
authors.forename: K
authors.initials: K
authors.lastname: Inoue
authors.forename: T
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Y
authors.initials: Y
authors.lastname: Kawahito
authors.forename: H
authors.initials: H
authors.lastname: Sano
mesh_terms: D000328:Adult; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use*; D003556:Cystitis / Q000139:chemically induced; D018450:Disease Progression; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009436:Neural Tube Defects / Q000139:chemically induced; D012008:Recurrence; D016312:Treatment Refusal; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003520:Cyclophosphamide